公开(公告)号：US20160296563A1

公开(公告)日：2016-10-13

申请号：US15038025

申请日：2014-11-21

Applicant: CELLECTIS

Inventor： David SOURDIVE ,  Carole DESSEAUX ,  Andrew SCHARENBERG

IPC: A61K35/17 ,  C07K14/725 ,  C12N5/0783

CPC classification number: A61K35/17 ,  A61K2039/5158 ,  C07K14/7051 ,  C12N5/0636 ,  C12N2510/00 ,  C12N2510/02

Abstract: The present invention relates to a method for generating batches of lymphocytes with averaged potency. In particular, the present invention relates to a method of pooling lymphocytes from different donors to avoid NK alloreactivity and anti-HLA immune response. Lymphocytes from each donor are inactivated for at least a gene encoding a TCR component, and are pooled together before be administrated to a subject in need thereof. Thus, this method allows generating batches of lymphocytes with averaged potency, particularly to treat cancer, viral infection or auto-immune disease. The present invention also relates to a batch of lymphocytes obtainable by this method. The batch of lymphocytes can be used to be administrated to one or several patients, being made available as an “off the shelf” therapeutic product, in particular to treat cancer, auto-immune disease or viral infection.

Abstract translation: 本发明涉及产生具有平均效力的淋巴细胞批次的方法。 特别地，本发明涉及汇集来自不同供体的淋巴细胞以避免NK同种异体反应性和抗HLA免疫应答的方法。 来自每个供体的淋巴细胞灭活至少一个编码TCR组分的基因，并在合并给有需要的受试者之前汇集在一起​​。 因此，该方法允许产生具有平均效力的淋巴细胞的批次，特别是治疗癌症，病毒感染或自身免疫疾病。 本发明还涉及可通过该方法获得的一批淋巴细胞。 该批淋巴细胞可以用于给一个或几个患者施用，其可作为“现成”治疗产品获得，特别是用于治疗癌症，自身免疫疾病或病毒感染。